Synta Pharmaceuticals, Inc. (SNTA) Tops Q2 EPS by 3c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/12/2026

1. MIRM
2. SPY
3. META
4. MSFT
5. PLTR
6. JNJ
7. HUM
8. CSCO
9. KTOS
10. NVDA

Go back to Synta Pharmaceuticals, Inc. (SNTA) Tops Q2 EPS by 3c

New CEO Whitaker is Positive for Synta Pharma (SNTA); Roth Affirms at 'Buy' Following Q2 Results

August 6, 2014 2:10 PM EDT

Roth Capital reaffirms its Buy rating and $27 target on Synta Pharmaceuticals, Inc. (Nasdaq: SNTA) following Q2 results and announcement of a... More

Synta Pharma (SNTA) Taps Sanofi's (SNY) Anne Whitaker as CEO

August 6, 2014 7:10 AM EDT

Synta Pharmaceuticals, Inc. (Nasdaq: SNTA) announced that Anne Whitaker will join the Company as President, Chief Executive Officer and a member of the Companys Board of Directors effective September 2, 2014. Ms. Whitaker has more than 20 years of experience in the pharmaceutical industry, principally at GlaxoSmithKline and Sanofi (NYSE: SNY) including,... More